top of page

The Co-Founder and CEO of HAYA Therapeutics describes the "dark genome" approach that led to a deal today with Eli Lilly for obesity and metabolic disease

  • Sep 4, 2024
  • 1 min read

Samir Ounzain explains the way HAYA studies how long non-coding RNAs, a once poorly understood component of the genome, affects disease and then targets it with therapeutics.



Join the BiotechTV mailing list

Thanks for subscribing!

Follow BiotechTV

  • Twitter
  • LinkedIn
  • Facebook
  • TikTok
  • Instagram

Also look for unique social pages for BiotechTV U.

Sponsor Spotlight

HSBC_IB_Stacked_logo.png

HSBC Innovation Banking's dedicated sector experts possess in-depth knowledge of the technology, life science and healthcare economies. With access to an extensive global network, we can help you fuel growth through venture capital and corporate investors, industry influencers, customers, and global opportunities.

Through our interconnected innovation hubs in the US, UK, Israel and Hong Kong, our experts are supporting the world’s innovation economy – both clients and their investors to help them meet their growth goals.

bottom of page